Priothera

About:

Priothera is developing the orally applied sphingosine 1 phosphate (S1P) receptor modulators for haematological malignancies.

Website: https://priothera.com

Top Investors: European Investment Bank, Bpifrance, Earlybird Venture Capital, HealthCap, Fountain Healthcare Partners

Description:

Priothera is a clinical-stage company developing orally applied sphingosine 1 phosphate (S1P) receptor modulators for haematological malignancies. We are dedicated to improving the lives of patients suffering from hematological malignancies by delivering an innovative immune modulator to enhance the curative potential of allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in these patients.